Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...

Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMTSalt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical ...

We recently published a list of the Top 10 AI Stocks Buzzing on Latest News. In this article, we are going to take a look at ...

Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered ...

Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

Salt Lake City-based accelerator Altitude Lab is hoping it can entice biotechs impacted by the uncertainty surrounding federal grants.

Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.

Built on top of Erlang, Elixir makes it easier to write good functional programming code and harder to mess it up. Here's a ...

Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

In August 2023, the Chandrayaan-3 mission successfully landed on the Moon, but a dilemma arose when scientists found that the ...